Koers Genocea Biosciences Inc Nasdaq
Aandelen
US3724271040
Biotechnologie & Medisch Onderzoek
Omzet 2020 | 1,36 mln. 1,27 mln. | Omzet 2021 | 1,64 mln. 1,53 mln. | Marktkapitalisatie | 66,64 mln. 62,1 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2020 | -43 mln. -40,07 mln. | Nettowinst (verlies) 2021 | -33 mln. -30,76 mln. | EV/omzet 2020 | 50,8 x |
Nettoliquiditeiten 2020 | 55,9 mln. 52,09 mln. | Nettoliquiditeiten 2021 | 19,96 mln. 18,61 mln. | EV/omzet 2021 | 28,4 x |
K/w-verhouding 2020 |
-2,18
x | K/w-verhouding 2021 |
-2,4
x | Werknemers | - |
Dividendrendement 2020 * |
-
| Dividendrendement 2021 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 52 | 01-03-07 | |
Girish Aakalu
PRN | Corporate Officer/Principal | - | 10-12-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 11-09-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,28% | 45,51 mld. | |
-9,94% | 38,52 mld. | |
+38,08% | 38,13 mld. | |
+28,09% | 30,74 mld. | |
-8,64% | 26,03 mld. | |
+11,69% | 25,92 mld. | |
+45,14% | 14,13 mld. | |
+33,65% | 12,73 mld. | |
-7,80% | 11,29 mld. |